Last reviewed · How we verify
NCT07420855: ARON-2PLUS
International Multicentric Retrospective Study on the Use of Enfortumab Vedotin + Pembrolizumab as First-line Therapy in Patients With Locally Advanced/Metastatic Urothelial Cancer (ARON-2PLUS)
trial in Locally Advanced or Metastatic Urothelial Cancer in 361 participants. Not yet recruiting.
1 November 2026
Quick facts
| Lead sponsor | Aron Research Foundation Ets |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 361 |
| Start date | 1 February 2026 |
| Primary completion | 1 November 2026 |
| Estimated completion | 1 December 2030 |
| Sites | 1 location across Italy |
Conditions studied
- Locally Advanced or Metastatic Urothelial Cancer — all drugs for Locally Advanced or Metastatic Urothelial Cancer →
- Urothelial Cancer — all drugs for Urothelial Cancer →
Sponsor
Aron Research Foundation Ets
Who can join
18 and older, any sex, with Locally Advanced or Metastatic Urothelial Cancer or Urothelial Cancer. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
overall survival in patients with la/mUC or rare GU tumors
Time frame: December 2030
time from the start of the therapy until death from any cause -
progression-free survival
Time frame: December 2030
time from the start of the therapy until progression or death from any cause.
Sponsor's own description
The ARON-2PLUS Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of Enfortumab vedotin plus Pembrolizumab as first-line therapy in patients with locally advanced/metastatic Urothelial Cancer. Two supplementary optional studies are designed: one is related to CT scans evaluation for 3D reconstruction analysis; the other one is an omic analysis on FFPE tissue.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07420855
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07420855 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aron Research Foundation Ets
- Last refreshed: 12 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07420855.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing